A randomized trial of immunotherapy for persistent genital warts

Area of Science:

• Immunology
• Dermatology
• Virology

Background:

• Recurrent genital warts pose a treatment challenge, often requiring repeated destructive therapies.
• The efficacy of immunotherapy using human papillomavirus (HPV) virus-like particles (VLPs) for recurrent genital warts is under investigation.

Purpose of the Study:

• To evaluate the effectiveness of HPV6 L1 VLP immunotherapy, without adjuvant, in reducing genital wart recurrence after destructive treatment.

Main Methods:

• A randomized, placebo-controlled, blinded study involving patients with recurrent genital warts undergoing destructive therapy.
• Participants received either VLP immunotherapy (1 µg, 5 µg, or 25 µg) or placebo immunotherapy at weeks 0 and 4.
• The primary outcome was the recurrence of visible genital warts assessed at week 8.

Main Results:

• In Brisbane, 5 µg and 25 µg doses of VLP immunotherapy significantly increased wart area reduction compared to placebo (71% vs. 50%).
• The 1 µg dose of VLP immunotherapy did not show a significant difference compared to placebo (42% vs. 50%).
• No significant reduction in wart area was observed in Wenzhou participants receiving VLP immunotherapy, where disease duration was shorter.

Conclusions:

• HPV VLP immunotherapy may aid in clearing recurrent genital warts, particularly when destructive therapies are unsuccessful.
• Treatment success appears inversely related to the duration of the disease prior to therapy.
• Higher doses of VLP immunotherapy demonstrated greater efficacy in reducing genital warts.